Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A slow cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy

ABSTRACT: We used microarray analysis to molecularly profile distinct tumour cell populations present in untreated and vismodegib-treated basal cell carcinomas.

ORGANISM(S): Mus musculus

PROVIDER: GSE117458 | GEO | 2018/10/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.

Project description: Not available

| S-EPMC6295195 | biostudies-literature

A slow cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy

Project description:A slow cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy

| PRJNA482149 | ENA

Thy1 Marks a Distinct Population of Slow-Cycling Stem Cells in the Mouse Epidermis

Project description:Here, we report a discrete population of keratinocytes, marked by Thy1, in the basal layer of the IFE. We find that basal keratinocytes expressing differential levels of Thy1 display distinct transcriptional signatures. Thy1+ keratinocytes do not express T cell markers, express a unique transcriptional profile, cycle significantly slower than epidermal progenitors and display significant expansion potential in vitro. Collectively, these results reveal a distinct stem cell population that plays a critical role in epidermal homeostasis and repair.

2022-05-24 | GSE203405 | GEO

Basal p21 controls population heterogeneity in cycling and quiescent cell cycle states.

Project description: Not available

| S-EPMC4205626 | biostudies-literature

When dormancy fuels tumour relapse.

Project description: Not available

| S-EPMC8209066 | biostudies-literature

Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma

Project description:Smoothened inhibitors are currently being investigated for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). The majority of BCC patients treated with vismodegib experience significant clinical benefit, however, a small number of patients develop resistance. Knowledge of resistance mechanisms can generate predictive biomarkers and is critical for the design of additional therapeutic strategies aimed at circumventing resistance. To investigate mechanisms of resistance to vismodegib in BCC we sequenced and profiled biopsies from patients who initially responded to treatment and subsequently progressed on drug. We find that resistance is associated with re-activation of the Hedgehog (Hh) pathway through diverse mechanisms, including concurrent copy number alterations in the downstream Hh pathway components SUFU and GLI2, as well as novel SMO mutations that reduce sensitivity to vismodegib. The latter fall into two classes: those that activate SMO and those that directly affect the vismodegib-binding pocket. Additionally, we observe evidence of clonal selection of SMO mutations and intra-tumor heterogeneity of resistance mechanisms, which implies diverse and combinatorial strategies are required to overcome resistance.

| EGAS00001000845 | EGA

Identification of slow-cycling cells in Ewing sarcoma

Project description:We identified slow-cycling cells (SCCs) in Ewing sarcoma using a label retention assay with CFSE. We labeled cells of SK-ES-1, an Ewing sarcoma cell line, with CFSE. After 5 days culture, we isolated cells retaining strong fluorescence (upper, ~10%) as SCCs and other cells (lower, ~90%) as non-slow-cycling cells (non-SCCs) using FACS AriaTM Ⅲ cell sorter.

2022-10-17 | GSE204671 | GEO

The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis.

Project description: Not available

| S-EPMC7407555 | biostudies-literature

Identification of TOR-responsive slow-cycling neoblasts in planarians

Project description:Epimorphic regeneration commonly relies on the activation of quiescent stem cells to drive new cell production. The planarian Schmidtea mediterranea is among the best regenerators in nature, thanks to its large population of adult stem cells, called neoblasts. While neoblasts have long been known to drive regeneration, whether a subset of neoblasts is reserved for this purpose is unknown. Here, we revisited the idea of reserved neoblasts by approaching neoblast heterogeneity from a regulatory perspective. By implementing a new fluorescence-activated cell sorting strategy in planarians, we identified a population of neoblasts defined by low transcriptional activity. These RNAlow neoblasts are relatively slow-cycling at homeostasis and undergo a morphological regeneration response characterized by cell growth at 48 hours post-amputation. At this time, RNAlow neoblasts proliferated in a TOR-dependent manner. Additionally, knockdown of the tumour suppressor Lrig-1, which is enriched in RNAlow neoblasts, resulted in RNAlow neoblast growth and hyperproliferation at homeostasis, and ultimately delayed regeneration. We propose that slow-cycling RNAlow neoblasts represent a regeneration-reserved neoblast population.

2020-12-31 | GSE157860 | GEO

Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells.

Project description: Not available

| S-EPMC5173096 | biostudies-literature